Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming.
CD44v6
Exosome biogenesis
Exosome message transfer
Non-cancer stem cell reprogramming
Pancreatic cancer stem cells
Tspan8
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
19 Mar 2019
19 Mar 2019
Historique:
received:
04
01
2019
accepted:
06
03
2019
entrez:
21
3
2019
pubmed:
21
3
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Cancer-initiating cell (CIC) exosomes (CIC-TEX) are suggested reprogramming Non-CIC. Mode of message transfer and engagement of CIC-markers being disputed, we elaborated the impact of CD44v6 and Tspan8 on the response of Non-CIC. Non-metastasizing CD44v6- and Tspan8-knockdown (kd) pancreatic cancer cells served as Non-CIC. CIC-TEX coculture-induced changes were evaluated by deep-sequencing and functional assays. Tumor progression was surveyed during in vivo CIC-TEX treatment. Deep-sequencing of CIC-TEX-cocultured CD44v6kd-Non-CIC revealed pronounced mRNA changes in signaling, transport, transcription and translation; altered miRNA affected metabolism, signaling and transcription. CIC-TEX coculture-induced changes in Tspan8kd-Non-CIC mostly relied on CIC-TEX-Tspan8 being required for targeting. CIC-TEX transfer supported apoptosis resistance and significantly promoted epithelial mesenchymal transition, migration, invasion and (lymph)angiogenesis of the kd Non-CIC in vitro and in vivo, deep-sequencing allowing individual mRNA and miRNA assignment to altered functions. Importantly, CIC-TEX act as a hub, initiated by CD44v6-dependent RTK, GPCR and integrin activation and involving CD44v6-assisted transcription and RNA processing. Accordingly, a kinase inhibitor hampered CIC-TEX-fostered tumor progression, which was backed by an anti-Tspan8 blockade of CIC-TEX binding. This in depth report on the in vitro and in vivo impact of CIC-TEX on CD44v6kd and Tspan8kd Non-CIC unravels hub CIC-TEX activity, highlighting a prominent contribution of the CIC-markers CD44v6 to signaling cascade activation, transcription, translation and miRNA processing in Non-CIC and of Tspan8 to CIC-TEX targeting. Blocking CIC-TEX binding/uptake and uptake-initiated target cell activation significantly mitigated the deleterious CIC-TEX impact on CD44v6kd and Tspan8kd Non-CIC.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-initiating cell (CIC) exosomes (CIC-TEX) are suggested reprogramming Non-CIC. Mode of message transfer and engagement of CIC-markers being disputed, we elaborated the impact of CD44v6 and Tspan8 on the response of Non-CIC.
METHODS
METHODS
Non-metastasizing CD44v6- and Tspan8-knockdown (kd) pancreatic cancer cells served as Non-CIC. CIC-TEX coculture-induced changes were evaluated by deep-sequencing and functional assays. Tumor progression was surveyed during in vivo CIC-TEX treatment.
RESULTS
RESULTS
Deep-sequencing of CIC-TEX-cocultured CD44v6kd-Non-CIC revealed pronounced mRNA changes in signaling, transport, transcription and translation; altered miRNA affected metabolism, signaling and transcription. CIC-TEX coculture-induced changes in Tspan8kd-Non-CIC mostly relied on CIC-TEX-Tspan8 being required for targeting. CIC-TEX transfer supported apoptosis resistance and significantly promoted epithelial mesenchymal transition, migration, invasion and (lymph)angiogenesis of the kd Non-CIC in vitro and in vivo, deep-sequencing allowing individual mRNA and miRNA assignment to altered functions. Importantly, CIC-TEX act as a hub, initiated by CD44v6-dependent RTK, GPCR and integrin activation and involving CD44v6-assisted transcription and RNA processing. Accordingly, a kinase inhibitor hampered CIC-TEX-fostered tumor progression, which was backed by an anti-Tspan8 blockade of CIC-TEX binding.
CONCLUSIONS
CONCLUSIONS
This in depth report on the in vitro and in vivo impact of CIC-TEX on CD44v6kd and Tspan8kd Non-CIC unravels hub CIC-TEX activity, highlighting a prominent contribution of the CIC-markers CD44v6 to signaling cascade activation, transcription, translation and miRNA processing in Non-CIC and of Tspan8 to CIC-TEX targeting. Blocking CIC-TEX binding/uptake and uptake-initiated target cell activation significantly mitigated the deleterious CIC-TEX impact on CD44v6kd and Tspan8kd Non-CIC.
Identifiants
pubmed: 30890157
doi: 10.1186/s13046-019-1129-8
pii: 10.1186/s13046-019-1129-8
pmc: PMC6425561
doi:
Substances chimiques
CD44v6 antigen
0
Hyaluronan Receptors
0
MicroRNAs
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Pagination
132Subventions
Organisme : Deutsche Krebshilfe
ID : 110836
Organisme : National Natural Science Foundation of China (CN)
ID : NSFC 81702877
Références
Dev Biol. 2001 Jul 15;235(2):388-96
pubmed: 11437445
Virchows Arch. 2003 May;442(5):444-52
pubmed: 12692724
Int J Cancer. 2005 Jun 10;115(2):224-30
pubmed: 15688385
Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11
pubmed: 16314869
Cell Signal. 2007 Mar;19(3):454-65
pubmed: 17085014
Life Sci. 2007 May 1;80(21):1921-43
pubmed: 17408700
Mol Cancer Res. 2008 Feb;6(2):222-30
pubmed: 18314483
Nat Rev Cancer. 2009 Jan;9(1):40-55
pubmed: 19078974
Neoplasia. 2009 Oct;11(10):1093-105
pubmed: 19794968
Adv Cancer Res. 2010;107:163-224
pubmed: 20399964
Nat Rev Cancer. 2012 May 11;12(6):425-36
pubmed: 22576165
Int J Biochem Cell Biol. 2012 Sep;44(9):1574-84
pubmed: 22728313
Biochem Biophys Res Commun. 2012 Sep 7;425(4):775-80
pubmed: 22885184
Oncol Rep. 2012 Nov;28(5):1869-74
pubmed: 22923171
Development. 2012 Oct;139(19):3471-86
pubmed: 22949611
Curr Opin Oncol. 2013 Jan;25(1):52-8
pubmed: 23159848
Oncogene. 2014 Jan 30;33(5):665-70
pubmed: 23318432
Oncogene. 2013 Oct 31;32(44):5191-8
pubmed: 23334333
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Int J Cancer. 2013 Jul 15;133(2):416-26
pubmed: 23338841
Neoplasia. 2013 Mar;15(3):281-95
pubmed: 23479506
Eur J Cancer. 2013 Sep;49(13):2934-48
pubmed: 23683890
Oncogene. 2014 Jan 30;33(5):537-8
pubmed: 23831568
Neuro Oncol. 2013 Oct;15(10):1353-65
pubmed: 23877317
Oncogene. 2014 Jul 24;33(30):4003-15
pubmed: 24096488
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):234-54
pubmed: 24273063
J Exp Clin Cancer Res. 2014 Jan 06;33:3
pubmed: 24387758
Mol Cancer. 2014 Mar 08;13:52
pubmed: 24606718
Onco Targets Ther. 2014 Mar 20;7:447-56
pubmed: 24672247
Cancer Metastasis Rev. 2014 Sep;33(2-3):695-720
pubmed: 24744103
Semin Cancer Biol. 2014 Oct;28:3-13
pubmed: 24769058
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
J Biol Chem. 2014 Aug 29;289(35):24043-58
pubmed: 25023279
Genes Cancer. 2014 May;5(5-6):212-25
pubmed: 25061504
Neuro Oncol. 2015 Feb;17(2):223-42
pubmed: 25155357
Cell Rep. 2014 Sep 11;8(5):1432-46
pubmed: 25159140
World J Gastroenterol. 2014 Sep 14;20(34):12118-31
pubmed: 25232247
Front Immunol. 2014 Sep 16;5:442
pubmed: 25278937
Front Physiol. 2014 Sep 19;5:364
pubmed: 25285080
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Cell Death Differ. 2015 Apr;22(4):677-89
pubmed: 25301071
Curr Cancer Drug Targets. 2015;14(9):832-49
pubmed: 25386656
Oncotarget. 2015 Feb 10;6(4):2366-84
pubmed: 25544774
Semin Cell Dev Biol. 2015 Apr;40:60-71
pubmed: 25721809
Asian Pac J Cancer Prev. 2015;16(5):1677-82
pubmed: 25773809
Cell Mol Biol (Noisy-le-grand). 2015 Mar 09;61(1):42-50
pubmed: 25817345
Semin Oncol. 2015 Apr;42 Suppl 1:S3-17
pubmed: 25839664
Oncotarget. 2015 Apr 20;6(11):8709-21
pubmed: 25909162
Curr Opin Cell Biol. 2015 Aug;35:69-77
pubmed: 26001269
World J Gastroenterol. 2015 May 28;21(20):6215-28
pubmed: 26034356
Oncol Rep. 2015 Aug;34(2):663-72
pubmed: 26035691
Cell Cycle. 2015 Aug 3;14(15):2473-83
pubmed: 26091251
J Control Release. 2015 Dec 10;219:278-294
pubmed: 26143224
Nat Rev Cancer. 2015 Sep;15(9):515-27
pubmed: 26289315
Cell Cycle. 2015;14(20):3220-30
pubmed: 26315616
Oncogene. 2016 Jun 16;35(24):3083-91
pubmed: 26500059
Gastroenterology. 2016 Feb;150(2):513-25.e10
pubmed: 26597578
Methods Mol Biol. 2016;1381:111-49
pubmed: 26667458
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Nat Rev Genet. 2016 May;17(5):272-83
pubmed: 27040487
Cancer Discov. 2016 Jul;6(7):754-69
pubmed: 27154822
Oncotarget. 2016 Jun 28;7(26):40630-40643
pubmed: 27270327
Elife. 2016 Jun 10;5:
pubmed: 27282385
Oncotarget. 2016 Aug 23;7(34):55409-55436
pubmed: 27419629
World J Gastroenterol. 2016 Jul 14;22(26):5971-6007
pubmed: 27468191
Amino Acids. 2017 Mar;49(3):425-439
pubmed: 27562794
Methods Mol Biol. 2016;1464:25-34
pubmed: 27858353
Crit Rev Oncog. 2016;21(3-4):203-219
pubmed: 27915972
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
J Extracell Vesicles. 2017 Mar 7;6(1):1286095
pubmed: 28326170
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):199-211
pubmed: 28408326
Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):55-63
pubmed: 28560289
Cancer Lett. 2017 Sep 10;403:1-12
pubmed: 28619525
Trends Cancer. 2016 Jul;2(7):329-331
pubmed: 28741535
Sci Signal. 2017 Nov 21;10(506):null
pubmed: 29162741
Nat Commun. 2017 Nov 24;8(1):1758
pubmed: 29170450
Oncogene. 2018 Mar;37(11):1472-1484
pubmed: 29321661
Eur J Clin Invest. 2018 Apr;48(4):null
pubmed: 29405291
Glia. 2018 Aug;66(8):1542-1565
pubmed: 29464861
Oncogene. 2018 Oct;37(40):5387-5402
pubmed: 29880877
Med Sci Monit. 2018 Jul 12;24:4807-4822
pubmed: 29997385
Am J Pathol. 1982 Feb;106(2):250-60
pubmed: 6278935